Papanicolaou test utilization and frequency of screening opportunities among women diagnosed with cervical cancer

Kathleen Decker, Alain Demers, Daniel Chateau, Grace Musto, Zoann Nugent, Robert Lotocki, Marion Harrison

ABSTRACT

Background: Although the importance of Papanicolaou (Pap) smear test screening in reducing the incidence of cervical cancer is well established, in 1994–95 one in 4 women in Manitoba aged 18 to 69 years reported never having had a Pap test or not having had a Pap test in the last 3 years. The objectives of this study were to examine the screening history of women in Manitoba diagnosed with invasive cervical cancer and to explore whether opportunities for screening were missed.

Methods: In this case-control study women aged 18 years and older who resided in Manitoba and were diagnosed with invasive cervical cancer between 1989 and 2001 were each matched by age and area of residence to 5 controls, (N = 4009). Conditional logistic regression analyses were used to examine the association between Pap test utilization and the likelihood of diagnosis with invasive cervical cancer. Generalized linear models using the negative binomial distribution were used to assess the association between cancer status and rates of prior Pap testing and of opportunities to be screened. Logistic generalized estimating equation models were used for the analysis of physician characteristics.

Results: Forty-six percent of women in Manitoba diagnosed with invasive cervical cancer and 67% of the control group had received a Pap test in the 5 years before the case’s diagnosis. After adjustment for age, income and residence, the rate of Pap testing was significantly higher in the control group (rate ratio [RR] = 1.57, 95% confidence interval [CI] 1.44–1.73). Conversely, when cervical cancer was the outcome, women who had not had Pap tests were more likely to be diagnosed with invasive cervical cancer (odds ratio [OR] = 2.77, 95% CI 2.30–3.30) than women who did have a Pap test. Although women diagnosed with invasive cervical cancer had fewer Pap tests, they had had as many opportunities to be screened as controls (RR = 1.04, 95% CI 0.96–1.12). Compared with urban family physicians, rural family physicians were less likely to provide Pap tests (OR = 0.68, 95% CI 0.58–0.80) and specialists were more likely to provide Pap tests (OR = 1.70, 95% CI 1.30–2.22).

Conclusions: Women who were diagnosed with invasive cervical cancer in the province of Manitoba, Canada, had fewer Pap tests but the same frequency of opportunities to be screened as matched controls. These results reinforce the need to educate women about cervical cancer screening and the importance of receiving Pap tests.

Kathleen Decker is the evaluator of Screening Programs for CancerCare Manitoba, Winnipeg, Man. Alain Demers is an epidemiologist and team leader with the Department of Epidemiology and Cancer Registry, CancerCare Manitoba. Daniel Chateau is a biostatistician with the Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, Winnipeg. Grace Musto is a programmer/analyst for the Department of Epidemiology and Cancer Registry, CancerCare Manitoba. Zoann Nugent is an epidemiologist with the Department of Epidemiology and Cancer Registry, CancerCare Manitoba. Robert Lotocki is the medical director of the Manitoba Cervical Cancer Screening Program and a gynecological oncologist at CancerCare Manitoba. Marion Harrison is the director of Screening Programs for CancerCare Manitoba.

Competing interests: None declared.

Funding source: CancerCare Manitoba Foundation

Correspondence: Kathleen Decker, Screening Programs, CancerCare Manitoba, 5-25 Sherbrook St., Winnipeg MB R3C 2B1; kathleen.decker@cancercare.mb.ca
Although rates of cervical cancer are low in Canada, the incidence of the disease could be further reduced by the detection of precursor lesions and early-stage cancers in large populations of asymptomatic women through screening with the Papanicolaou (Pap) test, promoting Pap testing among women and physicians, and appropriately following up abnormal results. Although the evidence that screening using a Pap test decreases the incidence of cervical cancer, and in spite of efforts to promote Pap testing, 1 in 4 women aged 18 to 69 who participated in Statistics Canada’s 1994–95 National Population Health Survey reported never having had a Pap test or not having a Pap test in the last 3 years.

Several reasons have been identified in the literature as to why women do not obtain cervical cancer screening. Patient factors that influence screening include socioeconomic and demographic characteristics, knowledge and attitudes about cervical cancer. The probability of being screened tends to increase with education and income, and is lower for non-Canadian born women, those who do not speak English and those who have negative beliefs about cancer. System and physician factors that influence screening include lack of regular health care, patients’ inability to access screening services, and missed opportunities to screen by health care providers. “Missed opportunities” are instances when a woman has contact with a health care provider but the provider does not perform or recommend the screening test when it would be appropriate to do so. Physician characteristics that have been associated with missed opportunities to provide preventive care such as a Pap test include type of specialty, education, physician gender and practice location.

The objectives of this study were to examine the screening history of women diagnosed with invasive cervical cancer, to explore whether there were missed opportunities for screening and to investigate the influence of physician characteristics on Pap test utilization in the province of Manitoba.

Methods

Study design and population. This study used a case-control design. Cases included all women 18 years of age and older residing in Manitoba who were diagnosed with invasive cervical cancer between 1989 and 2001. Eighteen years of age was chosen as a cut-off, as this is the youngest target age for the Manitoba Cervical Cancer Screening Program. Five controls were selected for each case. Women who had ever had cervical cancer or malignant neoplasms, excluding non-melanoma skin cancer, or who had had a total hysterectomy during the study period, were excluded. Only cases and controls who were Manitoba residents for the entire period from 1984 to 2001 were included (1984 was chosen to provide at least 5 years of data on cases diagnosed in 1989). Cases and controls were matched by age (±1 year) at the index date, and by area of residence at the time of the case’s diagnosis using the forward sortation area (FSA) (i.e., the first 3 characters of the postal code). Residence was also determined at the time of the case’s diagnosis. Urban residence included the cities of Winnipeg, Brandon, Portage and Thompson, each of which has a population of at least 10,000. All other areas of the province were considered rural. Ethics approval was received from the Health Research Ethics Board at the University of Manitoba and the Health Information Privacy Committee (HIPC) at Manitoba Health. This study was supported by a grant from the CancerCare Manitoba Foundation.

Data sources. Cases of cervical cancer were identified through the Manitoba Cancer Registry (MCR), while controls were identified through the Manitoba Health Insurance Plan Registration (MHPR) file. The MCR is a population-based registry that records all new cancer patients who are Manitoba residents at the time of diagnosis. The provincial Department of Health maintains the MHPR for the purpose of administering the Manitoba Health Insurance Plan. Manitoba residents are not required to pay a premium for health insurance, which ensures that virtually everyone in the province is included in the MHPR. A record on the MHPR is created when a person registers with the health insurance system. The record includes a termination date and code when a person dies or moves out of the province.

The Manitoba Physician Claims Database was used to determine Pap test utilization and hysterectomy status. This database is generated by claims filed by physicians for payment of services and includes a billing tariff code and the date of service. All 7 possible Pap test tariff codes were used in this study, including the code that laboratories use to receive payment. Although Manitoba Pap test guidelines recommend that women have a Pap test at least once every 2 years following 3 consecutive normal results on annual Pap tests, we chose a 5-year interval because not all women are screened according to the recommended guidelines. The 5-year time frame was intended to allow a sufficiently long interval in which screening could take place.

Physician data — including specialty, gender, graduation date and graduation location (Canadian v. foreign graduate) — were abstracted from the Physician Master File, which is a list of all Manitoba physicians with a billing number. A brief analysis of Pap test
frequency and physician type revealed that family practitioners, internal medicine specialists, obstetrician/gynecologists, general surgeons, emergency medicine physicians and pediatricians provided 99.99% of all Pap tests. Therefore, only physicians in these areas of practice were included in the study (N = 2419).

Data derived from the 1996 Canadian Census were used to estimate the patient’s income at the time of diagnosis by average household income per enumeration area (approximately 500 to 600 individuals and 150 to 200 households).

**Opportunity to be screened.** An opportunity to be screened was defined as any visit to a physician made during the 5 years before the diagnosis of the case, excluding visits that occurred fewer than 10 months after a Pap test; any visit during this time frame was not considered an opportunity to be screened because the woman did not need a screening Pap test. The 6 months before the diagnosis of the case was also excluded, to rule out Pap tests that might have been done for diagnostic rather than screening purposes.

**Data analysis.** Generalized linear regression models using the negative binomial distribution were conducted to assess the association between cancer status and rates of prior Pap testing and rates of opportunities to be screened (i.e., a matched cohort analysis). When invasive cervical cancer was treated as a dependent variable (i.e., case-control design), we conducted a conditional logistic regression analysis to examine the association between Pap test utilization and invasive cervical cancer. We tested for an interaction between region of residence and income, because other research in Manitoba has found this to be significant. For analyses examining physician characteristics, logistic generalized estimating equation models using an independent correlation matrix to account for correlated data within the dataset were conducted. This allowed for unbiased estimates of the association between the likelihood of having a Pap test at any given visit and various physician characteristics. Data analyses were performed using SAS Version 9.1 (SAS Institute, Cary, NC).

**Results**

**Rate of Pap testing.** A total of 4009 women were included in the study (666 cases and 3343 controls). The mean age at the time of diagnosis of invasive cervical cancer was 50 years. The mean income was $39 175 for cases and $42 280 for controls. Although cases and controls were matched by area of residence using postal code FSAs, average income is slightly different because it is based on enumeration areas, which are smaller than FSAs.

In the 5-year period before the diagnosis date of the case — excluding the 6 months before diagnosis — 63% of all women in the study received at least one Pap test, but this incidence was unevenly distributed between cases and controls (Table 1). Only 46.4% of cases had received a Pap test, compared with 66.8% of controls. The mean number of Pap tests over the 5-year period was 0.87 for cases and 1.38 for controls. The mean number of Pap tests for women who had received at least 1 Pap test was 2.62 for cases and 2.66 for controls.

After adjustment for age, income and residence, the rate of Pap tests was found to be significantly higher for controls than for cases (rate ratio [RR] = 1.57, 95% confidence interval [CI] 1.44–1.73) (Table 2). The rate of Pap tests decreased with age (RR = 0.80, 95% CI 0.78–0.81) and increased with income (RR = 1.06, 95% CI 1.04–1.07). Region of residence was also significant: urban women had a higher rate of Pap tests than rural women (RR 1.22, 95% CI 1.15–1.30). However, there was no interaction between region of residence and income in this analysis.

**Rate of cervical cancer diagnosis.** Analyses of the association between prior Pap testing and the development of cervical cancer indicated that women who had not had a Pap test in the 5 years before diagnosis were more likely to be diagnosed with invasive cervical cancer than women who had received a Pap test during that period (odds ratio [OR] = 2.77, 95% CI 2.30–3.30) (Table 3). Increasing income had an inverse effect on the likelihood of being diagnosed with invasive cervical cancer (OR = 0.78, 95% CI 0.69–0.89). The analysis did not include region of residence and age, as these variables were the basis for matching cases and controls and therefore would have no effect on the OR. However, an additional model tested the interaction between residence and income and found that the interaction was not significant.

**Screening opportunities.** The mean number of opportunities to be screened in the 5 years before diagnosis was 17.8 for cases and 18.2 for controls. Multivariate generalized linear analysis using the negative binomial distribution indicated no difference between cases and controls with respect to frequency of opportunities to be screened (RR = 1.04, 95% CI 0.96–1.12) (Table 4). Age at diagnosis and income both had a significant effect on frequency of opportunities to be screened; increasing age was associated with more frequent opportunities (RR = 1.20, 95% CI 1.18–1.22), while increasing income was associated with less frequent opportunities (RR = 0.94, 95% CI 0.92–0.95).
### Table 1: Characteristics and Pap test utilization of study participants in the 5-year period before diagnosis of invasive cervical cancer (N = 4009)

| Characteristics                                      | Cases (n = 666) | Controls (n = 3343) |
|-----------------------------------------------------|-----------------|---------------------|
| Mean age, years                                     | 50.0            | 50.1                |
| Mean income, $                                       | 39 175          | 42 280              |
| Rural residence (%)                                  | 203 (29.9)      | 1016 (30.0)         |
| Pap test (%)                                         | 309 (46.4)      | 2233 (66.8)         |
| Mean number of Pap tests (SD)                        | 0.87 (± 1.16)   | 1.38 (± 1.29)       |
| Mean number of Pap tests for women who had at least 1 (SD) | 2.62 (± 0.76)   | 2.66 (± 0.78)       |

SD = standard deviation

### Table 2: Adjusted rate ratios of Pap tests in the 5-year period before diagnosis of invasive cervical cancer

| Category                                             | Rate ratio (95% CI) |
|------------------------------------------------------|---------------------|
| Controls                                             | 1.57 (1.44–1.73)    |
| Cases (reference)                                    | 1.00                |
| Age (by 10-year increase)*                           | 0.80 (0.78–0.81)    |
| Income (by $10 000 increase)*                        | 1.06 (1.04–1.07)    |
| Urban                                                | 1.22 (1.15–1.30)    |
| Rural (reference)                                    | 1.00                |

*There is no reference category for age or income because they were treated as continuous variables in the analysis.

Note: A generalized linear regression models using the negative binomial distribution was used. Each rate ratio is adjusted for all other variables in the model. Pap test is the outcome and cervical cancer (case vs. control) is the predictor, so analyses appropriate for a matched cohort design were used.

CI = confidence interval

### Table 3: Adjusted odds ratios of being diagnosed with invasive cervical cancer*

| Category                                            | Odds ratio (95% CI) |
|-----------------------------------------------------|---------------------|
| No Pap test                                          | 2.77 (2.30–3.30)    |
| Pap test (reference)                                 | 1.00                |
| Income (by $10 000 increases)*                       | 0.78 (0.69–0.89)    |

*Includes the 5-year period before diagnosis of invasive cervical cancer.

*There is no reference category for income because income was treated as a continuous variable in the analysis.

Note: A conditional logistic regression was used to examine the association between Pap test utilization and invasive cervical cancer. This table does not include region of residence and age because these variables were the basis for matching cases and controls, and therefore would have no effect on the odds ratio.

CI = confidence interval
Area of residence (urban v. rural) had no effect on frequency of opportunities to be screened (RR = 1.02, 95% CI 0.96–1.09).

**Physician characteristics.** Compared with urban family practitioners, rural family practitioners were less likely (OR = 0.68, 95% CI 0.58–0.80) and specialists more likely (OR = 1.70, 95% CI 1.30–2.22) to provide Pap tests (Table 5).

Data on location of graduation (Canadian v. foreign), physician gender and practice type were available for 53% of the visits deemed an opportunity to be screened (N = 58 029 visits). All effects were adjusted for patient age, income and all other variables included in the model. Compared with foreign graduates, Canadian graduates were more likely to provide a Pap test (OR = 1.20, 95% CI 1.04–1.39). Female physicians were more likely to provide a Pap test than male physicians (OR = 1.99, 95% CI 1.75–2.26). As in the first model, rural family physicians were less likely (OR = 0.80, 95% CI 0.75–0.87) and specialists were more likely (OR = 4.39,
95% CI 4.09–4.70) to provide Pap tests than urban family physicians.

Discussion

The Pap test is one of the most effective tools available for the early detection of cervical cancer. However, optimal utilization levels have still not been reached. In this study, 36% of Manitoban women had not had a Pap test in a 5-year period. Although the mean number of Pap tests was slightly higher for controls in comparison with cases, the mean number of Pap tests for women who had received at least 1 Pap test was similar. This finding suggests that having at least 1 Pap test increases the likelihood of subsequent tests, and thus reinforces the importance of ensuring that testing is initiated. Women who had never had a Pap test were almost 3 times as likely to be diagnosed with invasive cervical cancer as women who had received at least 1 Pap test. However, although women diagnosed with invasive cervical cancer had fewer Pap tests, their opportunities to be screened were as frequent as those of study controls.

These findings in Manitoba are consistent with previous research that has investigated the relationship between history of Pap test utilization and the risk of cervical cancer; these studies also reported an increased risk of cervical cancer for non-recipients and irregular recipients of Pap testing.17–21 Women who lived in urban areas of Manitoba and those with higher incomes had more Pap tests and a lower risk of being diagnosed with cervical cancer. Other research has found that cervical screening is provided more consistently in urban areas than in rural areas, and that the incidence of Pap tests decreases with decreasing income.22–24 Studies in other jurisdictions have also found that a high percentage of women diagnosed with invasive cervical cancer had multiple contacts with the health care system in the 3 to 5 years before diagnosis, but had not been screened for cervical cancer.25–28

One possible reason for our finding that controls had as many opportunities to be screened as cases may be that under-screened women lack continuity of care and thus may be more likely to visit a physician for acute problems only. In Manitoba, a steady relationship between continuity of care and better preventive health care has been observed.29 Therefore, an ongoing relationship with a family practitioner is crucial, even in a health care system that provides universal access to care. Conversely, although preventive services might not traditionally be offered in walk-in clinics, these practice settings can be successful in doing so: 55% of patients who attended an inner-city walk-in clinic for an acute medical problem and who were inadequately screened accepted a same-day appointment for a Pap test.30 We also found that older women had more opportunities to be screened than younger women, likely because they visit a doctor more frequently. Women in higher income brackets had fewer opportunities to be screened than their counterparts in lower income brackets. This could be because these women do not need to visit a doctor as frequently, or because they had been receiving Pap tests on a regular basis, which would result in fewer of their health care visits being counted as an opportunity to be screened.

Our study found that certain physicians were more likely than others to provide a Pap test. The increased provision of Pap tests by specialists (including obstetricians/gynecologists) may relate to their specific training, a focus on women’s health and focused reasons for patient visits. Previous research has found that women who see obstetricians/gynecologists are more likely to be younger and have higher education and income levels that those who do not see these specialists, and therefore may request a Pap test more frequently.31 This is particularly worrisome, since women are less likely to see an obstetrician/gynecologist as they get older, yet cervical cancer incidence and mortality rates are higher among older women.3 Therefore, the physicians most likely to treat older women may be less likely to provide a Pap test.

Patients of female physicians were also more likely to receive Pap tests than patients of male physicians. Female physicians have been found to devote more time to preventive services than male physicians, even when patient gender and health status were controlled for in the analysis.32–34 Patients have been shown to prefer a physician of the same gender for genital and rectal examinations.35 However, in 1 study female patients were no more likely to refuse an examination from a male physician than from a female physician.33 The unavailability of a female chaperone may also affect male physicians’ likelihood of providing a Pap test. Nevertheless, obstetricians/gynecologists do not seem to experience these screening barriers to the same degree, based on their rates of Pap test provision.

This study has several important strengths. Many previous studies collected data from patient and physician surveys, introducing the possibility of non-response, recall, interviewer and acquiescence bias.30 By collecting Pap test history and health care provider information from linked Manitoba Health administrative databases whose reliability has been extensively evaluated, we eliminated these sources of bias in this study. Information on all cancer cases diagnosed over a 12-year period was available, making the study sample very comprehensive. Information on hysterectomy was also available, which was an
important limitation in previous studies that used administrative data to examine Pap test utilization.37

Our research, however, was not able to differentiate between a patient refusing to have a Pap test and a physician not offering the test. In addition, Pap tests processed at a public laboratory from salaried physicians who do not submit claims for the services they provide may not be captured, which could result in fewer Pap test being reported than were actually performed. However, it is estimated that the physician claims data captures at least 95% of all Pap tests performed in Manitoba.4,18 Data on whether a physician was a Canadian graduate, graduation year and physician sex were incomplete; therefore, the results must be interpreted cautiously. Finally, a previous case-control study that examined the screening history of women diagnosed with invasive cervical cancer removed cases of microinvasive cancer (International Federation of Gynecology and Obstetrics [FIGO] stage IA) from the main analyses because they have an excellent prognosis and may be considered a success of screening (most would not have been diagnosed in the absence of screening).5 In our study, only 15% of the cases for whom data on available were available were stage IA. We included stage IA cases because the likelihood of being diagnosed with invasive cervical cancer for women who did not have a Pap test was much larger than for women who did have a Pap test (OR = 2.77). If stage IA cases were removed, the effect of not having had a Pap test would likely be even larger. Moreover, their inclusion is unlikely to affect findings on the opportunity to be screened because we found no difference between the cases and controls.

Conclusion
The results of this study show that women who have been diagnosed with invasive cervical cancer had fewer Pap tests but had as many opportunities to be screened as matched controls. Although some women may not get a Pap test because they do not visit a health care provider, a lack of contact with the health care system is not the main reason why many women are under-screened. These results reinforce the necessity for health care providers to seek every opportunity to educate women about preventive cervical cancer screening and to provide Pap tests regardless of the setting of care and the continuity of the relationship with the patient.

References
1. Liu S, Semenciw R, Probert A, Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer. 2001;11(1):24–31.
2. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol. 1941;42(2):193–206.
3. Lee J, Parsons GF, Gentleman JF. Falling short of Pap test guidelines. Health Rep. 1998;10(1):9–19.
4. Roos LL, Traverse D, Turner D. Delivering prevention: the role of public programs in delivering care to high-risk populations. Med Care. 1999;37(6 Suppl):JS264–JS278.
5. Coughlin SS, Uhler RJ. Breast and cervical cancer screening practices among Asian and Pacific Islander women in the United States, 1994-1997. Cancer Epidemiol Biomarkers Prev. 2000;9(6):597–603.
6. Katz SJ, Hofer TP. Socioeconomic disparities in preventive care persist despite universal coverage. Breast and cervical cancer screening in Ontario and the United States. JAMA. 1994;272(7):530–534.
7. Jenkins CN, McPhee SJ, Bird JA, Pham GQ, Nguyen BH, Nguyen T, et al. Effect of a media-led education campaign on breast and cervical cancer screening among Vietnamese-American women. Prev Med. 1999;28(4):395–406.
8. Maxwell CJ, Banecz CM, Snider J, Vik SA. Factors important in promoting cervical cancer screening among Canadian women: findings from the 1996-97 National Population Health Survey (NPHS). Can J Public Health. 2001;92(2):127–133.
9. Mandelblatt JS, Gold K, O’Malley AS, Taylor K, Cagney K, Hopkins JS, et al. Breast and cervix cancer screening among multiethnic women: role of age, health, and source of care. Prev Med. 1999;28(4):418–425.
10. Gultiz E, Bustillo-Hernandez M, Kent EB. Missed cancer screening opportunities among older women: a review. Cancer Pract. 1998;6(5):289–295.
11. Van HR, Janz NK, Wolfe RA, Tedeschi PJ, Stross JK, Huang X, et al. Characteristics of primary care physicians and their practices associated with mammography rates for older women. Cancer. 2003;98(9):1811–1821.
12. Hyman I, Singh PM, Meana M, George U, Wells LM, Stewart DE. Physician-related determinants of cervical cancer screening among Caribbean women in Toronto. Ethn Dis. 2002;12(2):268–275.
13. Lurie N, Margolis KL, McGovern PG, Mink PJ, Slater JS. Why do patients of female physicians have higher rates of breast and cervical cancer screening. J Gen Intern Med. 1997;12(1):34–43.
14. Lurie N, Slater J, McGovern P, Ekstrom J, Quam L, Margolis K. Preventive care for women. Does the sex of the physician matter. N Engl J Med. 1993;329(7):478–482.
15. Manitoba CCSP. Manitoba Cervical Cancer Screening Program. Operations & statistical report, 2003 and 2004. Winnipeg (MB): CancerCare Manitoba: 2006.
16. Martens PJ, Fransoo R, The NToKT, Burland E, Jebsamani L, Burchill C, et al. The Manitoba RHA indicators atlas: population-based comparisons of health and health care use. Winnipeg (MB): Manitoba Centre for Health Policy: 2003.
17. Celentano DD, Klassen AC, Weisman CS, Rosenshein NB. Cervical cancer screening practices among older women: results from the Maryland Cervical Cancer Case-Control Study. J Clin Epidemiol. 1988;41(6):531–541.

18. Cohen MM. Using administrative data for case-control studies: the case of the Papanicolaou smear. Ann Epidemiol. 1993;3(1):93–98.

19. Carmichael JA, Jeffrey JF, Steele HD, Ohlde ID. The cytologic history of 245 patients developing invasive cervical carcinoma. Am J Obstet Gynecol. 1984;148(3):685–690.

20. Stuart GC, McGregor SE, Duggan MA, Nation JG. Review of the screening history of Alberta women with invasive cervical cancer. CMAJ. 1997;157(5):513–519.

21. Sasiemi PD, Cuzick J, Lynch-Farmerly E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer. 1996;73(8):1001–1005.

22. Goel V. Factors associated with cervical cancer screening: results from the Ontario Health Survey. Can J Public Health. 1994;85(2):125–127.

23. Harlan LC, Bernstein AB, Kessler LG. Cervical cancer screening: who is not screened and why? Am J Public Health. 1991;81(7):885–890.

24. Simees RJ, Newschaffer CJ, Hadrup N, Ali-Abarghoui F, Tao X, Mack N, et al. Predictors of compliance with recommended cervical cancer screening schedule: a population-based study. J Community Health. 1999;24(2):115–130.

25. Janerich DT, Hadjimichael O, Schwartz PE, Lowell DM, Meigs JW, Merino MJ, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health. 1995;85(6):791–794.

26. Makue DM, Freid VM, Kleinman JC. National trends in the use of preventive health care by women. Am J Public Health. 1989;79(4):21–26.

27. Norman SA, Talbott EO, Kuller LH, Krampe BR, Stolley PD. Demographic, psychosocial, and medical correlates of Pap testing: a literature review. Am J Prev Med. 1991;7(4):219–226.

28. Fruchtter RG, Boyce J, Hunt M. Missed opportunities for early diagnosis of cancer of the cervix. Am J Public Health. 1980;70(4):418–420.

29. Menec VH, Sirske M, Attawar D. Does continuity of care matter in a universally insured population? Health Serv Res. 2005;40(2):389–400.

30. Doyle JP, Parker RM, Jacobson TA, McNagny SE. Breast and cervical cancer screening in an inner-city medical walk-in clinic: taking advantage of an often missed opportunity. Am J Prev Med. 1996;12(5):345–50.

31. Montañó DE, Phillips WR. Cancer screening by primary care physicians: a comparison of rates obtained from physician self-report, patient survey, and chart audit. Am J Public Health. 1995;85(6):795–800.

32. Franks P, Bertakis KD. Patient-centered communication in primary care: physician and patient gender and gender concordance. J Women’s Health. 2003;12(1):73–80.

33. Levy S, Dowling P, Boult L, Monroe A, McQuade W. The effect of physician and patient gender on preventive medicine practices in patients older than fifty. Fam Med. 1992;24(1):58–61.

34. Bertakis KD, Helms LJ, Callahan EJ, Azari R, Robbins JA. The influence of gender on physician practice style. Med Care. 1995;33(4):407–416.

35. Fennema K, Meyer DL, Owen N. Sex of physician: patients’ preferences and stereotypes. J Fam Pract. 1990;30(4):441–446.

36. Bowman JA, Redman S, Dickinson JA, Gibberd R, Sanson-Fisher RW. The accuracy of Pap smear utilization self-report: a methodological consideration in cervical screening research. Health Serv Res. 1991;26(1):97–107.

37. Chattopadhyay SK, Ebrahim SH, Tao G, McKenna MT. Use of cervical cancer screening among insured women: the extent of missed opportunities. Health Policy. 2004;73(2):194–201.

Acknowledgments: The authors gratefully acknowledge the CancerCare Manitoba Foundation for supporting this study. The results and conclusions are those of the authors. No official endorsement by Manitoba Health is intended or should be inferred.

Citation: Decker K, Demers A, Chateau D, Musto G, Nugent Z, Lotocki R, Harrison M. Papanicolaou test utilization and frequency of screening opportunities among women diagnosed with cervical cancer Open Med 2009;3(3):140-147.

Published: 11 August 2009

Copyright: Open Medicine applies the Creative Commons Attribution Share Alike License, which means that anyone is able to freely copy, download, reprint, reuse, distribute, display or perform this work and that authors retain copyright of their work. Any derivative use of this work must be distributed only under a license identical to this one and must be attributed to the authors. Any of these conditions can be waived with permission from the copyright holder. These conditions do not negate or supersede Fair Use laws in any country.